Indivior Pharmaceuticals Inc (INDV) 은(는) 상장 기업입니다 헬스케어 섹터의 Drug Manufacturers - Specialty & Generic 산업에서 운영. 본사 소재지는 North Chesterfield, VA, 미국. 현재 CEO는 Joseph J. Ciaffoni.
INDV 을(를) 보유 IPO 날짜 2014-12-29, 1,030 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $4.06B.
Indivior PLC is a specialty pharmaceutical company focused on developing and commercializing prescription medications for substance use disorders, serious mental illnesses, and opioid overdose. The company's marketed portfolio includes SUBLOCADE and SUBUTEX PRO, buprenorphine extended-release monthly injections; SUBOXONE sublingual films and tablets; SUBUTEX sublingual tablets; OPVEE nasal spray for opioid overdose reversal; and PERSERIS for schizophrenia treatment. Indivior maintains a robust pipeline with multiple clinical and preclinical programs, including INDV-2000 for opioid use disorder, INDV-1000 for alcohol use disorder, and several collaborative development programs addressing opioid, cannabis, and other substance use disorders. Headquartered in North Chesterfield, Virginia, the company operates across the United States, United Kingdom, and international markets.
